[go: up one dir, main page]

MX350295B - Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluor o-4-yodo-fenilamino)-isonicotinamida. - Google Patents

Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluor o-4-yodo-fenilamino)-isonicotinamida.

Info

Publication number
MX350295B
MX350295B MX2014014520A MX2014014520A MX350295B MX 350295 B MX350295 B MX 350295B MX 2014014520 A MX2014014520 A MX 2014014520A MX 2014014520 A MX2014014520 A MX 2014014520A MX 350295 B MX350295 B MX 350295B
Authority
MX
Mexico
Prior art keywords
isonicotinamide
phenylamino
dihydroxy
fluoro
propyl
Prior art date
Application number
MX2014014520A
Other languages
English (en)
Other versions
MX2014014520A (es
Inventor
Bankston Donald
Saal Christoph
Becker Axel
Kuehn Clemens
Poma Marco
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2014014520A publication Critical patent/MX2014014520A/es
Publication of MX350295B publication Critical patent/MX350295B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)

Abstract

La invención se refiere a formas en estado sólido de N-((S)-2,3-dihidroxi-propil)-3-(2-fluoro-4-yodo-fenilamino)-isoni cotinamida, a procesos para su preparación y a sus usos médicos.
MX2014014520A 2012-05-30 2013-05-07 Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluor o-4-yodo-fenilamino)-isonicotinamida. MX350295B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653037P 2012-05-30 2012-05-30
PCT/EP2013/001352 WO2013178320A1 (en) 2012-05-30 2013-05-07 Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide

Publications (2)

Publication Number Publication Date
MX2014014520A MX2014014520A (es) 2015-02-24
MX350295B true MX350295B (es) 2017-09-04

Family

ID=48537929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014520A MX350295B (es) 2012-05-30 2013-05-07 Formas en estado solido de n-((s)-2,3-dihidroxi-propil)-3-(2-fluor o-4-yodo-fenilamino)-isonicotinamida.

Country Status (30)

Country Link
US (1) US9260393B2 (es)
EP (1) EP2855434B1 (es)
JP (1) JP6280543B2 (es)
KR (1) KR20150022923A (es)
CN (1) CN104334530A (es)
AR (1) AR091186A1 (es)
AU (1) AU2013269994B2 (es)
BR (1) BR112014029838A2 (es)
CA (1) CA2875145C (es)
CL (1) CL2014003285A1 (es)
DK (1) DK2855434T3 (es)
EA (1) EA028059B1 (es)
ES (1) ES2592860T3 (es)
HK (1) HK1206733A1 (es)
HR (1) HRP20161135T1 (es)
HU (1) HUE028850T2 (es)
IL (1) IL235947A (es)
LT (1) LT2855434T (es)
MX (1) MX350295B (es)
MY (1) MY169266A (es)
NZ (1) NZ701103A (es)
PL (1) PL2855434T3 (es)
PT (1) PT2855434T (es)
RS (1) RS55167B1 (es)
SG (1) SG11201407842TA (es)
SI (1) SI2855434T1 (es)
TW (1) TWI570108B (es)
UA (1) UA112899C2 (es)
WO (1) WO2013178320A1 (es)
ZA (1) ZA201409426B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
US10179132B2 (en) 2015-05-26 2019-01-15 Industry-Academic Cooperation Foundation, Yonsei University Composition for inducing differentiation of multipotent neural stem cells into dopaminergic neurons and method for inducing differentiation of multipotent neural stem cells into dopaminergic neurons by using the same
KR20160138756A (ko) * 2015-05-26 2016-12-06 연세대학교 산학협력단 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
MY194462A (en) 2016-11-25 2022-11-30 Genuv Inc Composition for Promoting Differentiation of and Protecting Neural Stem Cells and Method for Inducing Neural Regeneration using same
KR101833412B1 (ko) 2017-07-24 2018-02-28 연세대학교 산학협력단 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010014360A (ko) * 1997-07-01 2001-02-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 2-(4-브로모 또는 4-요오도 페닐아미노)벤조산 유도체 및ｍｅｋ 억제제로서의 그의 용도
KR20010108093A (ko) * 1999-01-13 2001-12-07 로즈 암스트롱, 크리스틴 에이. 트러트웨인 1-헤테로고리 치환된 디아릴아민
WO2003101988A2 (en) * 2002-05-31 2003-12-11 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
AR051248A1 (es) * 2004-10-20 2007-01-03 Applied Research Systems Derivados de 3-arilamino piridina
CN102134218A (zh) * 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂

Also Published As

Publication number Publication date
UA112899C2 (uk) 2016-11-10
IL235947A (en) 2016-08-31
HRP20161135T1 (hr) 2016-11-04
RS55167B1 (sr) 2017-01-31
US9260393B2 (en) 2016-02-16
SI2855434T1 (sl) 2016-10-28
AU2013269994A1 (en) 2015-01-22
LT2855434T (lt) 2016-12-12
AU2013269994B2 (en) 2017-04-20
NZ701103A (en) 2016-09-30
ZA201409426B (en) 2017-05-31
IL235947A0 (en) 2015-02-01
EP2855434B1 (en) 2016-06-22
AR091186A1 (es) 2015-01-14
SG11201407842TA (en) 2014-12-30
TWI570108B (zh) 2017-02-11
MY169266A (en) 2019-03-20
PL2855434T3 (pl) 2016-12-30
EP2855434A1 (en) 2015-04-08
CA2875145A1 (en) 2013-12-05
CN104334530A (zh) 2015-02-04
JP2015518013A (ja) 2015-06-25
JP6280543B2 (ja) 2018-02-14
DK2855434T3 (en) 2016-09-12
HUE028850T2 (en) 2017-01-30
ES2592860T3 (es) 2016-12-01
KR20150022923A (ko) 2015-03-04
PT2855434T (pt) 2016-10-04
EA201401341A1 (ru) 2015-05-29
US20150152059A1 (en) 2015-06-04
EA028059B1 (ru) 2017-10-31
WO2013178320A1 (en) 2013-12-05
HK1206733A1 (en) 2016-01-15
TW201400459A (zh) 2014-01-01
MX2014014520A (es) 2015-02-24
BR112014029838A2 (pt) 2017-06-27
CA2875145C (en) 2021-01-12
CL2014003285A1 (es) 2015-03-06

Similar Documents

Publication Publication Date Title
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
UA109010C2 (en) Morpholino pyrividines and their use in therapy
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
MX363456B (es) Compuestos para tratar atrofia muscular espinal.
PH12015501609A1 (en) Phenicol antibacterials
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
GB201209587D0 (en) Therapeutic compounds
TW201613864A (en) Novel compounds
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
MX343689B (es) Formulaciones combinadas de darunavir.
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX341976B (es) Formulaciones de darunavir.
WO2014043252A3 (en) Hydroxypyridinone-,hydroxypyrimidinone-and hydroxypyridazinone drivatives and their therapeutic application
NZ701103A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
IN2014KN02584A (es)
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders

Legal Events

Date Code Title Description
FG Grant or registration